

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Drini, M;Wong, NC;Scott, HS;Craig, JM;Dobrovic, A;Hewitt, CA;Dow, C;Young, JP;Jenkins, MA;Saffery, R;Macrae, FA

Title:

Investigating the potential role of genetic and epigenetic variation of DNA methyltransferase genes in hyperplastic polyposis syndrome

Date:

2011-02-25

Citation:

Drini, M., Wong, N. C., Scott, H. S., Craig, J. M., Dobrovic, A., Hewitt, C. A., Dow, C., Young, J. P., Jenkins, M. A., Saffery, R. & Macrae, F. A. (2011). Investigating the potential role of genetic and epigenetic variation of DNA methyltransferase genes in hyperplastic polyposis syndrome. Plos One, 6 (2), <https://doi.org/10.1371/journal.pone.0016831>.

Persistent Link:

<https://hdl.handle.net/11343/263937>

License:

CC BY

Investigating the Potential Role of Genetic and Epigenetic Variation of DNA Methyltransferase Genes in Hyperplastic Polyposis Syndrome

Musa Drini^{1,2*}, Nicholas C. Wong³, Hamish S. Scott⁴, Jeffrey M. Craig³, Alexander Dobrovic^{5,6}, Chelsee A. Hewitt⁵, Christofer Dow⁷, Joanne P. Young⁸, Mark A. Jenkins⁹, Richard Saffery³, Finlay A. Macrae¹

1 Colorectal Medicine and Genetics, Royal Melbourne Hospital, Department of Medicine, University of Melbourne, Parkville, Victoria, Australia, **2** Gastroenterology and Hepatology Department, Canberra Hospital, Garran, Australian Capital Territory, Australia, **3** Developmental Epigenetics, Murdoch Childrens Research Institute, Department of Paediatrics, University of Melbourne, Royal Children's Hospital, Parkville, Victoria, Australia, **4** Institute of Medical and Veterinary Science, Adelaide, Australia, **5** Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia, **6** Department of Pathology, University of Melbourne, Parkville, Victoria, Australia, **7** Anatomical Pathology, Royal Melbourne Hospital, Parkville, Victoria, Australia, **8** Queensland Institute of Medical Research, Herston, Queensland, Australia, **9** MEGA Epidemiology, School of Population Health, University of Melbourne, Carlton, Victoria, Australia

Abstract

Background: Hyperplastic Polyposis Syndrome (HPS) is a condition associated with multiple serrated polyps, and an increased risk of colorectal cancer (CRC). At least half of CRCs arising in HPS show a CpG island methylator phenotype (CIMP), potentially linked to aberrant DNA methyltransferase (DNMT) activity. CIMP is associated with methylation of tumor suppressor genes including regulators of DNA mismatch repair (such as *MLH1*, *MGMT*), and negative regulators of Wnt signaling (such as *WIF1*). In this study, we investigated the potential for interaction of genetic and epigenetic variation in *DNMT* genes, in the aetiology of HPS.

Methods: We utilized high resolution melting (HRM) analysis to screen 45 cases with HPS for novel sequence variants in *DNMT1*, *DNMT3A*, *DNMT3B*, and *DNMT3L*. 21 polyps from 13 patients were screened for *BRAF* and *KRAS* mutations, with assessment of promoter methylation in the *DNMT1*, *DNMT3A*, *DNMT3B*, *DNMT3L*, *MLH1*, *MGMT*, and *WIF1* gene promoters.

Results: No pathologic germline mutations were observed in any DNA-methyltransferase gene. However, the T allele of rs62106244 (intron 10 of *DNMT1* gene) was over-represented in cases with HPS ($p < 0.01$) compared with population controls. The *DNMT1*, *DNMT3A* and *DNMT3B* promoters were unmethylated in all instances. Interestingly, the *DNMT3L* promoter showed low levels of methylation in polyps and normal colonic mucosa relative to matched disease free cells with methylation level negatively correlated to expression level in normal colonic tissue. *DNMT3L* promoter hypomethylation was more often found in polyps harbouring *KRAS* mutations ($p = 0.0053$). *BRAF* mutations were common (11 out of 21 polyps), whilst *KRAS* mutations were identified in 4 of 21 polyps.

Conclusions: Genetic or epigenetic alterations in *DNMT* genes do not appear to be associated with HPS, but further investigation of genetic variation at rs62106244 is justified given the high frequency of the minor allele in this case series.

Citation: Drini M, Wong NC, Scott HS, Craig JM, Dobrovic A, et al. (2011) Investigating the Potential Role of Genetic and Epigenetic Variation of DNA Methyltransferase Genes in Hyperplastic Polyposis Syndrome. PLoS ONE 6(2): e16831. doi:10.1371/journal.pone.0016831

Editor: Robert Oshima, Sanford-Burnham Medical Research Institute, United States of America

Received: August 28, 2010; **Accepted:** January 14, 2011; **Published:** February 10, 2011

Copyright: © 2011 Drini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Hicks Foundation supported MD. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: musa.drini@act.gov.au

Introduction

Hyperplastic Polyposis Syndrome (HPS) is a colorectal cancer (CRC) predisposition associated with the development of multiple serrated polyps, and is defined by the World Health Organization as:

- (1) at least five serrated polyps proximal to the sigmoid colon with two or more of these being >10 mm; or
- (2) any number of serrated polyps proximal to the sigmoid colon in an individual who has a first-degree relative with serrated polyps; or

(3) >20 serrated polyps of any size, but distributed throughout the colon. The implied meaning of this last criterion is that the polyps are not all present in the rectum [1].

HPS is the genetic disease model for the *serrated neoplasia pathway* of CRC development [2–4]. This new distinct pathway of CRC is characterized by activating mutation of the *BRAF* proto-oncogene (specifically V600E) and widespread and concordant gene promoter hypermethylation (CpG Island methylation Phenotype or CIMP) [5–8], and is responsible for silencing of many genes by CpG island methylation in specific cancer subtypes [9]. CIMP positive CRC cancers have distinct clinico-pathological features

including proximal location, mucinous histopathology, female preponderance, and a high frequency of *BRAF* mutation [7,10–12]. DNA methylation disturbances are also a feature of HPS with a large proportion of *BRAF* mutation positive HPS polyps being CIMP positive [13,14]. Increased DNA methylation in 14 markers (*MINTs* 1,2 and 31, *p16*, *MGMT*, *MLH1*, *RASSF1*, *RASSF2*, *NORE1*, *RKIP*, *MTST1*, *DAPK*, *FAS* and *CHFR*) in small hyperplastic polyps and in normal mucosa of patients with HPS suggests that there may be a genetic basis for this observation [6].

The aberrant DNA methylation found in the CIMP phenotype may be a consequence of a dysfunction in the machinery involved in establishing and maintaining normal DNA methylation [15]. DNA methyltransferases (DNMTs) are a family of proteins responsible for transfer of methyl groups specifically to cytosine in CpG dinucleotides of DNA [16,17]. Four DNMTs (*DNMT1* [18], *DNMT3A*, *DNMT3B* [19–21], and *DNMT3L* [22,23]) have been extensively characterized in mammals. *DNMT1* acts primarily on hemi-methylated double stranded DNA following DNA replication to faithfully maintain methylation patterns in daughter cells [24,25]. *DNMT3A* and *-3B* are involved in de novo methylation, establishing tissue-specific DNA methylation marks during development [26,27]. *DNMT3L* lacks the methyltransferase catalytic domain [28] and is thought to facilitate the action of other DNMTs by enhancing their targeting to specific loci for DNA methylation [29].

Dysregulation of DNMTs has been linked to many cancers [30], and may play a role in the CIMP phenotype in CRC [31]. Indeed recent evidence suggests that overexpression of *DNMT3B* in particular shows a significant association with CIMP high CRC [32,33]. Given the observation that even apparently normal mucosa in patients with HPS is highly methylated [6], we investigated the potential for mutation or epigenetic disruption of *DNMT1* (CCDS12228.1), *DNMT3A* (CCDS1718.1), *DNMT3B* (CCDS13204.1) and *DNMT3L* (CCDS13705.1) in the development of HPS.

Materials and Methods

Patient Selection

The Melbourne Health Human Research Ethics Committee approved the study (HREC2007.081) and all participants provided written informed consent to take part. We utilized the clinical database of The Royal Melbourne Hospital Bowel Cancer Surveillance Service and the Familial Cancer Clinic, to identify patients satisfying the diagnostic criteria for HPS. Detailed patient demographics, polyp number, size, location, pedigree, family and personal history of CRC and histopathology were prospectively collected (Table 1 and Table 2).

DNA sequence data on this paper have been previously reported on the GenBank database.

Polyps were reviewed by a histopathologist with an interest in the HPS (CD). The use of the term *serrated polyp* in this report encompasses polyps with serrated architecture and includes microvesicular hyperplastic polyps, and sessile serrated polyps with or without dysplasia. Traditional serrated adenoma and adenoma were not considered in this report. We classified lesions as advanced polyps if the size of the lesion was 10 mm or more.

Control colon tissue was obtained during colonoscopy from patients who presented with abdominal pain for investigation and completed endoscopic examination was normal.

Peripheral blood was collected for germline mutation analysis and immortalized EBV transformed lymphoblast cell lines (LCLs) were generated. If surveillance colonoscopy was performed, polyp tissue was collected and stored in RNALater (Ambion-Applied Biosystems).

Table 1. Patients' demographics.

Number of cases with HPS	45
Median age years (range)	61 (28–82)
Female	21
Median age at diagnosis	49 (26–78)
Median number of HP per case	37.5
Number of patients with HPs >10 mm	18
Patients with 5 or more coexisting adenomas	13
Number of cases who had partial/total colectomy for 11/5 CRC/HPS	
Number of families with HPS	2
Number of patients with FHx of CRC (FDR)	20
Personal history of CRC	11
Median age of patients with CRC	47.5

Thirty-six cases from this cohort have been previously reported [66]. CRC-colorectal cancer, FDR-first degree relative.
doi:10.1371/journal.pone.0016831.t001

Total DNA extraction

LCLs (lymphoblast cell lines) were available from 45 patients with HPS. DNA was extracted from all cases using DNeasy 96 Blood and Tissue kits according to the manufacturer's instructions (Qiagen, Hilden, Germany). In addition, DNA was extracted from

Table 2. Clinico-pathological characteristics of cases: DNMT promoter methylation analysis and *BRAF/KRAS* mutation.

Cases	HPs location	Classification of polyps	Size	<i>BRAF/KRAS</i> mutation
1	Sigmoid colon	SSA	10 mm	KRAS
2	Descending colon	SSA	8 mm	WT
3	Rectum	MVHP	5 mm	KRAS
	Transverse colon	MVHP	6 mm	KRAS
	Transverse colon	MVHP	7 mm	WT
4	Sigmoid colon	MVHP-SSA	9 mm	BRAF
	Sigmoid colon	MVHP	5 mm	BRAF
5	Transverse colon	MVHP	6 mm	BRAF
	Splenic flexure	MVHP	5 mm	BRAF
6	Descending colon	HP	9 mm	BRAF
7	Ascending colon	SSA	7 mm	BRAF
	Transverse colon	Mixed HP/SSA	5 mm	KRAS
	Descending colon	SSA	9 mm	BRAF
8	Rectum	SSA	5 mm	BRAF
9	Ascending colon	SSA	12 mm	WT
10	Rectum	SSA	4 mm	BRAF
11	Transverse colon	Mixed HP/SSA	6 mm	WT
12	Transverse colon	SSA	8 mm	BRAF
	Transverse colon	SSA	5 mm	WT
13	Rectum	SSA	9 mm	BRAF
	Sigmoid colon	HP	5 mm	WT

SSA-sessile serrated polyp; HP-typical hyperplastic polyp; MVHP- microvesicular hyperplastic polyp.

doi:10.1371/journal.pone.0016831.t002

21 polyps obtained from 13 different HPS cases. DNA concentration and quality was assessed by absorbance spectrophotometry and agarose gel electrophoresis.

RNA Isolation and Real-Time Reverse-Transcription PCR

Total RNA was isolated using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions, followed by treatment with Turbo DNA-free (Ambion/Applied Biosystems, Austin, TX, USA) to remove contaminating genomic DNA. Reverse transcription using random hexamers was performed with SuperScript VILO cDNA Synthesis Kit (Invitrogen). To determine expression levels of genes of interest, quantitative RT-PCR using SYBR Green-based analysis and Master Mix (Invitrogen) was carried out with 10 μ M sense and antisense primers (primers on request). Reactions were performed in triplicate and analysed using an ABI 7300 Sequence Detection System (Applied Biosystems). Relative expression levels were determined using the standard Δ Ct method with GAPDH housekeeping gene used for normalisation.

Germline mutation detection

We employed High Resolution Melting (HRM) analysis as a novel and cost effective method to search for the presence of unknown variants in DNMT genes, from 45 cases with available genomic DNA. DNA was first amplified by real time PCR in the presence of LightCycler[®] 480 High Resolution Melting Dye using a LightCycler[®] 480 System (Roche Applied Sciences). After the PCR, the successive melting curve experiment was performed in the same apparatus. Gene scanning software was used to identify sequence variation by melt profiling. PCR and DNA melting were performed in triplicate. PCR was optimized with titration of MgCl₂ and variation in annealing temperatures. In brief, 10 ng genomic DNA was used in the PCR, Master mix (Roche Applied Sciences), and final forward and reverse primer (concentration 0.2 μ M). Sense and antisense PCR primers for *DNMT* genes were designed using consensus coding sequences: *DNMT1* (CCDS12228.1), *DNMT3A* (CCDS1718.1), *DNMT3B* (CCDS13204.1) and *DNMT3L* (CCDS13705) [34]. When amplicon length exceeded 300 bp or nonspecific product was evident following electrophoresis on a 2% agarose gel, we designed alternative primer pairs using the Primer3 software package (http://biotools.umassmed.edu/bioapps/primer3_www.cgi). The online POLAND program was used to confirm that amplicons contained a single melting domain [35].

Somatic mutation detection for BRAF and KRAS

High resolution melting (HRM) analysis was performed using a LightCycler[®] 480 (Roche Diagnostics, Penzberg, Germany) in a modification of the previously published method of [36]. The reaction mixture contained: 1x PCR buffer, DNA template, 200 μ M dNTPs (Fisher Biotec Australia, Wembley, Western Australia), 5 μ M SYTO[®] 9 (Invitrogen, Carlsbad, CA), and 0.5 U HotStarTaq polymerase (Qiagen, Germantown, MD, USA). Various concentrations of MgCl₂ and primers (primers on request) were used specific to each assay in a 10 μ l final reaction volume. PCR reactions were performed in triplicate.

Quantitative DNA methylation analysis by MALDI-TOF MassARRAY EPITYPING and bisulphite sequencing

DNA was extracted from 21 polyps (13 cases with HPS) and 5 controls (colonic mucosa from non-HPS cases) using the DNeasy kit (Qiagen). Bisulphite conversion was performed using the MethylEasy Xceed kit according to manufacturer's instructions (Human Genetic Signatures, Sydney, Australia) 1–2 μ g of genomic DNA was used for bisulphite conversion. The converted

DNA was eluted to a final concentration of 20 ng/ μ l. 20 ng of converted DNA was used for PCR amplification.

We employed SEQUENOM EpiTYPER analysis [37] for detection and quantitation of DNA methylation of the promoter regions of *DNMT1*, *DNMT3A*, *DNMT3B* and *DNMT3L*. In brief, genomic DNA was bisulphite treated using MethylEasy Xceed kit (Human Genetic Signatures), PCR amplification was performed using primers directed to the promoter regions of the *DNMT* genes (primers on request). Amplicons were then subjected to the EpiTYPER chemistry. Briefly, amplicons were treated with shrimp alkaline phosphatase treatment followed by *in vitro* transcription and base specific cleavage (SEQUENOM, San Diego, CA). Samples were then analysed by MALDI-TOF mass spectroscopy and the methylation ratios obtained using EpiTYPER v1.0.5 software (SEQUENOM). Further analysis and cleaning of data was performed using the R statistical package (<http://www.cran.org>) and scripts developed in house. This included identification and removal of CpG units that overlapped with other peaks following mass spectroscopy. Further data cleaning and curation was then performed in R to remove CpG units that did not yield data in at least 70% of samples. Samples, from which less than 40% of CpG units yielded data, were also not included in subsequent analyses.

The *DNMT3L* amplicons were subjected to cloning and DNA sequencing as outlined in [38]. Amplicons were cloned into pGEMT-Easy Vector (Promega, Madison, WI, USA) and then transformed into DH5- α *E. coli*. Positive clones were selected for automated DNA sequencing performed by the Australian Genome Research Facility (AGRF, Melbourne, Australia). Sequencing data was then analysed using BiQ-Analyzer [39].

Statistical analysis

After data cleaning and curation of SEQUENOM assays, data was analysed using the Heatmap.2 function in R whereby unsupervised hierarchical clustering of the samples and CpG units was performed. Dendrograms and associated heatmaps were generated according to the DNA methylation ratio of specific CpG units and samples analysed. Geometric means methylation levels were calculated for each tissue type, prior to statistical analysis using a Student's t-test.

A box and whisker plot was generated in R to display the distribution of DNA methylation ratios between polyp and germline tissues across the *DNMT3L* promoter. Calculations were performed to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for the associations between allele frequency and disease. All statistical tests were two-sided and P-value, 0.05 was considered as a significant level of statistical evidence to reject the null hypothesis. All statistical analyses were done using Stata 10.0.

Results

DNA methyltransferase exon scanning by High Resolution Melting (HRM) Analysis

In order to ascertain whether the previously reported methylation disruption associated with HPS may be due to genetic variability in DNMTs, we screened a total of 92 *DNMT* exons for novel mutations by HRM analysis in LCL genomic DNA from HPS subjects. This comprised 40 exons from *DNMT1*, 17 from *DNMT3A*, 24 from *DNMT3B* and 11 from *DNMT3L*. We found three previously identified single nucleotide polymorphisms (SNPs) in *DNMT1* (synonymous rs721186 and rs2228613) and intronic (rs62106244) and one SNP in *DNMT3A* (synonymous rs2276598) (Table 3).

Table 3. SNPs identified with HRM on germline DNA.

Gene	SNP ID	Exon/Intron	DNA change	Clinical association
<i>DNMT1</i>	rs721186	Exon	C/T	Unknown
<i>DNMT1</i>	rs62106244	Intron	C/T	Unknown
<i>DNMT1</i>	rs2228613	Exon	A/C	Unknown
<i>DNMT3A</i>	rs2276598	Exon	C/T	Unknown

doi:10.1371/journal.pone.0016831.t003

The T allele of the rs62106244 C>T variant (Fig. 1) was present in 7 out of 45 cases all of whom were heterozygous. To establish the frequency of this uncharacterised variant in the Caucasian population generally, we scanned 300 control samples, and found 16 that were heterozygous at this site. Chi-square analysis confirmed a statistically significant over representation of both the CT genotype and T allele in HPS cases ($\chi^2 = 6.66$, $p = 0.01$; $\chi^2 = 7.45$, $p < 0.01$ respectively). We observed that cases with HPS were approximately three times more likely to carry the variant (15.6%) compared to controls (5.3%), and this difference was statistically significant ($p = 0.01$). However, given the rarity of the variant the confidence intervals were wide (relative risk = 2.9; 95% confidence interval 1.1 to 6.5). *DNMT3B* and *DNMT3L* exon scanning did not reveal any SNPs in our HPS cases.

Quantitative methylation analysis of CRC CIMP-associated genes and DNMTs

Previous studies using a small number of patients with HPS and methylation specific PCR (MSP) have identified elevated levels of specific promoter methylation in both polyps and normal mucosa relative to non-diseased mucosa from subjects with sporadic serrated polyps [6]. This includes methylation of the *MGMT* and *MLH1* genes. In this study, we measured DNA methylation of the *IGF2* differentially methylated region (DMR), *H19*, *MGMT*, *MLH1* and *WIF1* promoters. Contrary to previous reports [40]; [13,14] we found that, *MGMT* and *MLH1* were unmethylated (Fig. S1) in both polyps and matched normal mucosa, while there was no significant difference in DNA methylation of *IGF2*, *H19*, and *WIF1* (Fig. S1) between polyp and disease free tissue.

In addition to examining CIMP markers, we also examined the potential for methylation based dysregulation of the *DNMT* genes themselves. Little data is available regarding methylation status of

this family of genes in non-diseased somatic tissue, and only limited studies have examined this in disease [41,42]. We studied DNA methylation of the promoter region of the *DNMT1*, -3A and -3B genes in HPS cases, comparing polyp-derived DNA, normal mucosa from the same patient (where available), and mucosa from controls with no disease. All three promoter regions were generally unmethylated in both polyp and normal mucosal tissue, with less than 10% methylation detected by SEQUENOM EpiTYPER (data not shown). We also found no evidence of promoter methylation of these genes in LCL genomic DNA (data not shown).

Interestingly, we found that *DNMT3L* was hypomethylated in both normal gut mucosa (mean methylation 0.33, SD 0.24, $n = 12$) and polyp tissue (mean methylation 0.36, SD 0.25 $n = 21$) relative to matched LCL DNA (mean 0.57, SD 0.24 $n = 19$); see unsupervised clustering figure 2A and box and whisker plot figure 2B). This difference was highly significant ($p = 5.1 \times 10^{-9}$ Student's t-test) and was confirmed by bisulphite sequencing (Fig. 3). We were unable to test expression level directly in HPS samples due to a lack of RNA, however a negative correlation between mean methylation and expression level was found in normal colonic tissue ($R = -0.64$; Fig. 4).

KRAS mutation may correlate with DNMT3L promoter methylation

CIMP and *BRAF* mutation are hallmarks of serrated tumours and *BRAF* V600E has been proposed as an important biological marker for HPS specific cancers [43]. We performed *BRAF* (V600E) and *KRAS* screening with HRM on DNA from serrated polyps derived from HPS cases and controls. Consistent with previous published data [7,44] we found that the *BRAF* V600E mutation was common in serrated polyps (11 out of 21) whereas the *KRAS* mutation was evident in only 4 out of 21. *KRAS* mutations were found primarily in polyps located in the transverse colon (two) and rectum (two). Interestingly one patient had two polyps with the *BRAF* somatic mutation and one with the *KRAS* somatic mutation, all within the right colon from the same patient. Examination of the level of *DNMT3L* promoter methylation and *KRAS* mutation-containing polyps revealed an association between these distinct genetic and epigenetic modifications (Table 4).

Polyps with *KRAS* mutations were far more likely to show *DNMT3L* promoter methylation at levels similar to those found in LCLs ($p = 0.0053$). In contrast, polyps with the *BRAF* mutation did not show any significant association with *DNMT3L* promoter methylation.




Figure 1. Normalized and temp-shifted difference plot for *DNMT1* gene SNP rs62106244. *Seven cases were heterozygous for rs62106244. The top arrow shows the sequence of the *DNMT1* gene.
doi:10.1371/journal.pone.0016831.g001




Figure 2. Unsupervised hierarchical clustering of the level of methylation of DNA from LCLs and somatic DNA in HPS cases for CpG_1 (analytic unit 1), CpG_6.7 (unit 2), CpG_8 (unit 3) and CpG_10 (unit 6) of the *DNMT3L* promoter region (A); Box and whisker plot comparing quantitative methylation between polyp tissue (white boxes) and peripheral blood (grey boxes) for each CpG site (B).

doi:10.1371/journal.pone.0016831.g002

Discussion

Given the significant association of HPS and associated tumours with increasing levels of aberrant promoter methylation (CIMP), including extensive methylation in the normal mucosa, and the role of DNMTs in both the establishment and maintenance of DNA methylation in humans, we examined the potential

association of genetic and epigenetic disruption of DNMTs in HPS.

Genetic variation in the *DNMT1* gene is potentially associated with HPS

Variants in *DNMT1* have been identified as risk factors for disease including systemic lupus erythematosus [45]. Genetic deficiency of *DNMT3B* causes ICF syndrome, a recessive human disorder characterised by immunodeficiency, centromere instability, and facial anomalies [46]. Variants in other DNMTs (i.e. *DNMT3L*, *DNMT1*) have been associated with human cancers [47–50]. Recently, a rare variant of *DNMT3L* was specifically associated with reduced methylation of sub-telomeric regions in humans [51]. In this study we demonstrated that HPS is not




Figure 3. *DNMT3L* bisulphite sequencing: HP40RH_LCL lymphoblastic cell line DNA, HP40RH_P polyp DNA and normal mucosa DNA HP40RH_N. Each line represents a sequenced clone and DNA methylation information is presented as a circle denoting the CpG site where methylation could occur. Black circles represent methylated CpG's while white circles represent unmethylated CpG's. The promoter of *DNMT3L* was observed to be less methylated in normal mucosa and polyp tissue but methylated in lymphoblastic cell line DNA.

doi:10.1371/journal.pone.0016831.g003




Figure 4. Correlation between mean methylation of *DNMT3L* promoter and gene expression level in control mucosa tissue. Mean was calculated from the combined methylation values for CpG units, 1, 2, 3 and 6.

doi:10.1371/journal.pone.0016831.g004

Table 4. Quantitative methylation (%) of DNMT gene promoters: 21 serrated polyps stratified by BRAF and KRAS mutation.

	Mean <i>DNMT1</i> methylation (%)	Mean <i>DNMT3A</i> methylation (%)	Mean <i>DNMT3B</i> methylation (%)	Mean <i>DNMT3L</i> methylation (%)
Polyps with BRAF mutation	3.3 [^]	4.3 [^]	21 [^]	37*
Polyps with <i>KRAS</i> mutation	2.8 [^]	4.1 [^]	27 [^]	55**
Polyps WT for BRAF and <i>KRAS</i>	3.6	4.4	25	30

[^]p-value <0.05 for DNMT1, DNMT3A and DNMT3B.

*p-value = 0.147 (BRAF/WT).

**p-value: = 0.0053 (*KRAS*/WT).

doi:10.1371/journal.pone.0016831.t004

associated with germline mutations of the *DNMT3A*, *-3B*, or *-3L* genes. Although we identified SNPs in both *DNMT1* and *DNMT3A* in HPS cases, these were generally detected at similar frequencies in non-diseased subjects and were predicted to be non-pathogenic.

The exception was rs62106244, located in the *DNMT1* gene, that was found to have a significantly higher frequency in HPS cases in comparison with controls. This SNP is not predicted to alter *DNMT1* splicing or protein, and is not evolutionarily conserved beyond primates [52]. Corresponding intronic SNPs, in other genes, have previously been associated with many diseases, including some cancers [53]. In fact as many as 45% of all trait/disease-associated SNPs identified in genome-wide association studies are intronic [54] with the pathogenic mechanisms underlying such associations remaining largely unclear. In addition, the level of linkage disequilibrium (LD) of rs62106244 in relation to other variants (i.e. haplotype status) has not yet been determined, although the entire *DNMT1* gene lies in a large block of LD.

Common CIMP markers are absent in most HPS lesions

Perturbation of DNA methylation and loss of gene function is well documented in MSI-H CRC [55]. However, the role of aberrant DNA methylation in *precancerous* lesions remains poorly understood despite its widespread occurrence. It has been reported that alteration of DNA methylation in hepatocellular carcinoma (HCC) evolves through precancerous lesions to multistage hepatocarcinogenesis [56]. In comparison with non-diseased tissue, human cancers generally show variations in both global DNA methylation (hypomethylation) and gene-specific (hyper- or hypo methylation) status [16,57].

Promoter methylation of *MLH1* in MSI-H sporadic colon cancers represents a classical example of aberrant methylation leading to cancer [12]. We did not find any evidence of aberrant methylation in HPS “precancerous lesions” for this traditional CIMP marker or for the *MGMT* gene. DNA methylation at other markers (*IGF2*, *WIF1* and *H19*) was also found to be unaffected in this group of HPS cases. *MLH1* methylation is associated with high-level MSI and this is in turn usually observed in areas of dysplasia or overt carcinoma. Similarly, methylation of *MGMT* is more likely to be seen in conjunction with *KRAS* mutation. Our findings in polyps therefore are not inconsistent with published reports.

DNMT3L is specifically hypomethylated in gut mucosa and HPS

Our data from a candidate gene approach to explore epigenetic abnormalities in HPS revealed a general lack of *DNMT1*,

DNMT3A and *DNMT3B* methylation as expected in non-diseased mucosal tissue. However, *DNMT3L*, usually silenced in somatic tissues by methylation, was found to be *hypomethylated* in both HPS polyps and normal gut mucosa relative to LCLs. There was no statistically significant difference between matched normal mucosa and polyps derived from the same cases, or between colonic mucosa from HPS cases and controls (colonic mucosa from cases with normal endoscopic findings and no history of polyps). We also found elevated methylation levels in all other somatic tissues tested including kidney, peripheral blood mononuclear cells, skeletal muscle, brain, and skin fibroblasts (data not shown), suggesting that the decreased methylation seen in gut mucosa is of functional significance. This was further supported by gene expression analysis that confirmed a inverse correlation between mean methylation and gene expression levels. In mice, methylation of the *DNMT3L* promoter has been unequivocally linked to gene silencing [58], and it has been shown that this gene is primarily expressed in thymus, testis and ovaries [23,59]. We have now added gut mucosa to the list of tissues expressing this gene. Recently the loss of DNA methylation at the *DNMT3L* promoter was found to be a positive biomarker for cervical cancer [60]. *DNMT3L* over expression in cervical cancer cells increases cellular proliferation, anchorage independent growth and nuclear reprogramming of cells, all central events in tumour development [61].

An interaction between *DNMT3L* methylation and *KRAS* mutation?

Previous studies that have examined the relationship between *BRAF* and *KRAS* mutations in a wide range of colonic polyp and cancer tissue have found a mutually exclusive distribution of these mutations [7]. *DNMT3L* methylation percentage across all CpG sites analysed for cases with *BRAF* and *KRAS* mutation revealed increased methylation of the *DNMT3L* promoter in cases with a *KRAS* mutation when compared with polyps with the normal variant ($p = 0.0053$), however due to small number of cases this observation need to be investigated in a larger number of polyps harbouring *KRAS* mutation. Additionally we found both *BRAF* and *KRAS* mutations in a single case (two polyps harbouring *BRAF* mutation and one polyp with *KRAS* mutation), which, though relatively rare, has been previously described [44]. Lesions harbouring *KRAS* mutations have been associated with distal location within the colorectum [62] MSI-L status [63] and unfavourable prognosis [64]. Our findings with regard to *DNMT3L* methylation and *KRAS* mutation need to be investigated further as recently aberrant promoter hypomethylation of *DNMT3L* has been linked with cervical cancer tumorigenesis [60]. The increased *DNMT3L* methylation seen in *KRAS* mutated

polyps is commensurate with the lower levels of methylation generally seen in these polyps relative to those with *BRAF* mutations.

Conclusions

To date, there is no single genetic abnormality known to underlie HPS. In addition, factors determining the transition to colon carcinoma remain unknown. There have been several reports implicating *DNMT* dysregulation in carcinogenesis [41,65]. However, the degree to which DNMTs may contribute to the development of precancerous lesions remains poorly understood. This study represents the first investigation of the possible role of the DNMT family of genes in the development of HPS. The data generated do not exclude a functional role of DNMT dysregulation in the development of HPS and associated disorders, however no exonic germline mutations were discovered, suggesting that regulation of DNMTs may occur via alternative mechanisms in this condition. It is interesting to speculate that the observed hypomethylation of the *DNMT3L* promoter in normal gut mucosa in the HPS patients identified here, may also play a role in the aberrant *de novo* establishment of tumour suppressor methylation seen in most CRC.

References

- Burt R, Jass JR (2000) Hyperplastic Polyposis In: Hamilton SR, Aaltonen LA, eds. Pathology and Genetics of Tumours of Digestive System. Lyon: IARC Press. pp 135–136.
- Jass JR (2000) Serrated adenoma of the colorectum and the DNA-methylator phenotype. *Nat Clin Pract Oncol* 2(8): 398–405.
- Snover DC, Jass JR, Fenoglio-Preiser C, Batts KP (2005) Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. *Am J Clin Pathol* 124(3): 380–91.
- Goldstein NS (2006) Serrated pathway and APC (conventional)-type colorectal polyps: molecular-morphologic correlations, genetic pathways, and implications for classification. *Am J Clin Pathol* 125(1): 146–53.
- Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with *BRAF* mutation in colorectal cancer. *Nat Genet* 38(7): 787–93.
- Minoo P, Baker K, Goswami R, Chong G, Foulkes WD, et al. (2006) Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. *Gut* 55(10): 1467–74.
- Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, et al. (2004) *BRAF* mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. *Gut* 53(8): 1137–44.
- Chan TL, Zhao W, Leung SY, Yuen ST (2003) *BRAF* and *KRAS* mutations in colorectal hyperplastic polyps and serrated adenomas. *Cancer Res* 63(16): 4878–81.
- Kondo Y, Issa JP (2004) Epigenetic changes in colorectal cancer. *Cancer Metastasis Rev* 23(1–2): 29–39.
- van Rijnsoever M, Grieco F, Elsaleh H, Joseph D, Iacopetta B (2002) Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. *Gut* 51(6): 797–802.
- Toyota M, Ohe-Toyota M, Ahuja N, Issa JP (2000) Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. *Proc Natl Acad Sci* 97(2): 710–5.
- Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, et al. (2004) Colorectal cancer with mutation in *BRAF*, *KRAS*, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. *J Clin Oncol* 22(22): 4584–94.
- O'Brien MJ, Yang S, Clebanoff JL, Mulcahy E, Farrar FA, et al. (2004) Hyperplastic (serrated) polyps of the colorectum: relationship of CpG island methylator phenotype and K-ras mutation to location and histologic subtype. *Am J Surg Pathol* 28(4): 423–34.
- Chan AO, Issa JP, Morris JS, Hamilton SR, Rashid A (2002) Concordant CpG island methylation in hyperplastic polyposis. *Am J Pathol* 160(2): 529–36.
- Issa JP, Shen L, Toyota M (2005) CIMP, at last. *Gastroenterology* 129(3): 1121–4.
- Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. *Nat Rev Genetics* 3(6): 415–428.
- Frigola J, Song J, Stürzaker C, Hinshelwood RA, Peinado MA, et al. (2006) Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. *Nature Genetics* 38(5): 540–549.
- Bestor TH (1998) GAMETOGENESIS '98: Methylation and the Unequal Developmental Potentials of the Oocyte and Sperm Genomes. *Am J Hum Genet* 62: 1269–1273.
- Okano M, Xie S, Li E (1998) Dnmt2 is not required for *de novo* and maintenance methylation of viral DNA in embryonic stem cells. *Nucleic Acid Research* 26: 2536–2540.
- Okano M, Bell DW, Haber DA, Li E (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for *de novo* methylation and mammalian development. *Cell* 99(3): 247–57.
- Xie S, Wang Z, Okano M, Nogami M, Li Y, et al. (1999) Cloning, expression and chromosome locations of the human DNMT3 gene family. *Gene* 236(1): 87–95.
- Aapola U, Kawasaki K, Scott HS, Ollila J, Vihinen M, et al. (2000) Isolation and initial characterization of a novel zinc finger gene, DNMT3L, on 21q22.3, related to the cytosine-5-methyltransferase 3 gene family. *Genomics* 65(3): 293–8.
- Webster K, O'Bryan MK, Fletcher S, Crewther PE, Aapola U, et al. (2005) Meiotic and epigenetic defects in Dnmt3L-knockout mouse spermatogenesis. *PNAS* 102(11): 4068–4073.
- Gruenbaum Y, Cedar H, Razin A (1982) Substrate and sequence specificity of a eukaryotic DNA methylase. *Nature* 295: 620–22.
- Flynn J, Glickman JF, Reich NO (1996) Murine DNA cytosine-C5 methyltransferase: pre-steady- and steady-state kinetic analysis with regulatory DNA sequences. *Biochemistry* 35(23): 7308–15.
- Kaneda M, Okano M, Hata K, Sado T, Tsujimoto N, et al. (2004) Essential role for *de novo* DNA methyltransferase Dnmt3a in paternal and maternal imprinting. *Nature* 429(6994): 900–3.
- Dodge JE, Okano M, Dick F, Tsujimoto N, Chen T, et al. (2005) Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization. *J Biol Chem* 280(18): 17986–91.
- Aapola U, Lyle R, Krohn K, Antonarakis SE, Peterson P (2001) Isolation and initial characterization of the mouse Dnmt3l gene. *Cytogenet Cell Genet* 92(1–2): 122–6.
- Jia D, Jurkowska RZ, Zhang X, Jeltsch A, Cheng X (2007) Structure of Dnmt3a bound to Dnmt3L suggests a model for *de novo* DNA methylation. *Nature* 449(7159): 248–51.
- Kanai Y, Hirohashi S (2007) Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. *Carcinogenesis* 28(12): 2434–42.
- Issa JP (2004) CpG island methylator phenotype in cancer. *Nat Rev Cancer* 4(12): 988–93.
- Nosho K, Shima K, Irahara N, Kure S, Baba Y, et al. (2009) DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. *Clin Cancer Res* 15(11): 3663–71.
- Ibrahim AE, Arends MJ, Silva AL, Wyllie AH, Greger L, et al. (2010) Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplasia progression. *Gut* 223602 Published Online.
- Sjöholm T, Jones S, Wood LD (2006) The consensus coding sequences of human breast and colorectal cancers. *Science* 314: 268–274.
- Steger G (1994) Thermal denaturation of double-stranded nucleic acids: prediction of temperatures critical for gradient gel electrophoresis and polymerase chain reaction. *Nucleic Acid Research* 22(14): 2760–2768.

Supporting Information

Figure S1 Quantitative methylation analysis (%) with SEQUE-NOM: genes analysed *H19*, *MGMT*, *MLH1*, *WIFI*, *BRAF* and *KRAS*. Samples: S1, S13, S10, S11 and S26 were disease free tissue. (TIF)

Acknowledgments

We thank Dr Justine Ellis and Dr Lavinia Gordon for help with statistical analysis.

Author Contributions

Conceived and designed the experiments: MD NCW RS HSS FAM. Performed the experiments: MD NCW HSS CAH RS. Analyzed the data: MD NCW RS JMC HSS AD JPY. Contributed reagents/materials/analysis tools: RS JMC HSS. Wrote the manuscript: MD NCW HSS RS JMC FAM AD. Made polyps histopathology assessment: CD. Contributed on biostatistics with regard to data analysis and critical review of manuscript: MAJ.

36. Krypuy M, Newnham GM, Thomsa DM, Conron M, Dobrovic A (2006) High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. *BMC Cancer* 6(295).
37. Ehrich M, Correll D, van den Boom D (2006) Introduction to EpiTYPER for Quantitative DNA Methylation Analysis Using the MassARRAY System. *Sequenome*.
38. Wong N, Morley R, Saffery R, Craig J (2008) Archived Guthrie blood spots as a novel source for quantitative DNA methylation analysis. *Biotechniques* 45(4): 423–4.
39. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, et al. (2005) BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. *Bioinformatics* 21(21): 4067–4068.
40. Yang S, Farraye FA, Mack C, Posnik O, O'Brien MJ (2004) BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. *Am J Surg Pathol* 28(11): 1452–9.
41. Roll JD, Rivenbark AG, Jones WD, Coleman WB (2008) DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. *Mol Cancer* 7: 15.
42. Jin B, Tao Q, Peng J, Soo HM, Wu W, et al. (2008) DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function. *Hum Mol Genet* 17(5): 690–709.
43. Minoo P, Moyer M, Jass J (2007) Role of BRAF-V600E in the serrated pathway of colorectal tumorigenesis. *J Pathol* 212(2): 124–133.
44. Carvajal-Carmona L, Howarth K, Lockett M, Polanco-Echeverry G, Volikos E, et al. (2007) Molecular classification and genetic pathways in hyperplastic polyposis syndrome. *J Pathol* 212: 378–385.
45. Park B, Kim LH, Shin HD, Park YW, Uhm WS, et al. (2004) Association analysis of DNA methyltransferase-1 (DNMT1) polymorphism with systemic lupus erythematosus. *J Hum Genet* 49(11): 642–6.
46. Hansen RS, Wijimenga C, Luo P, Stanek AM, Canfield CM, et al. (1999) The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. *Proc Natl Acad Sci* 96(25): 14412–14417.
47. Kelmen LE, Sellers TA, Schildkraut JM, Cuninghame JM, Vierkant RA, et al. (2008) Genetic variations in the one-carbon transfer pathway and ovarian cancer risk. *Cancer Res* 68(7): 2498–506.
48. Cebrian A, Pharoah PD, Ahmed S, Ropero S, Fraga MF, et al. (2006) Genetic variants in epigenetic genes and breast cancer risk. *Carcinogenesis* 27(8): 1661–9.
49. Lee SJ, Jeon HS, Jang JS, Park SH, Lee GY, et al. (2005) DNMT3B polymorphisms and risk of primary lung cancer. *Carcinogenesis* 26(2): 403–9.
50. Montgomery KG, Liu MC, Eccles DM, Campbell IG (2004) The DNMT3B C-T promoter polymorphism and risk of breast cancer in a british population: a case-control study. *Breast cancer Research* 6: R390–R394.
51. El-Maarri O, Karet MS, Mikeska T, Becker T, Diaz-Lacava A, et al. (2009) A systematic search for DNA methyltransferase polymorphisms reveals a rare DNMT3L variant associated with subtelomeric hypomethylation. *Hum Mol Genet* 26: 26.
52. Perta M, Lin X, Salzberg SL (2001) GeneSplicer: a new computational method for splice site prediction. *Nucleic Acid Res* 29(5): 1185–90.
53. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, et al. (2009) Genoma-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. *Nat Genet* 41(9): 986–90.
54. Hindorf L, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. (2009) Potential etiologic and functional implications of genome-wide association loci for human disease and traits. *Proc Natl Acad Sci* 106(23): 9362–7.
55. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, et al. (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. *Proc Natl Acad Sci* 95(12): 6870–5.
56. Kanai Y, Ushijima S, Tsuda H, Sakamoto M, Sugimura T, et al. (1996) Aberrant DNA methylation on chromosome 16 is an early event in hepatocarcinogenesis. *Japanese journal of cancer research* 87(12): 1210–1217.
57. Ushijima T, Watanabe N, Shimizu K, Miyamoto K, Sugimura T, et al. (2005) Detection and interpretation of altered methylation patterns in cancer cells. *Nat Rev Cancer* 5(3): 223–231.
58. Kato Y, Kaneda M, Hata K, Kumaki K, Hisano M, et al. (2007) Role of the Dnmt3 family in de novo methylation of imprinted and repetitive sequences during male germ cell development in the mouse. *Hum Mol Genet* 16(19): 2272–80.
59. Bourc'his D, Xu GL, Lin CS, Bollman B, Bestor TH (2001) Dnmt3L and the establishment of maternal genomic imprints. *Science* 294: 2536–2539.
60. Gokul G, Gautami B, Malathi S, Sowjanya AP, Polli UR, et al. (2007) DNA Methylation Profile at the DNMT3L Promoter: A Potential Biomarker for Cervical Cancer. *Epigenetics* 2(2): 80–85.
61. Gokul G, Ramakrishna G, Khosla S (2009) Reprogramming of HeLa cells upon DNMT3L overexpression mimics carcinogenesis. *Epigenetics* 4(5): 322–9.
62. Boss JL (1987) Prevalence of ras gene mutations in human colorectal cancers. *Nature* 327: 293–297.
63. Jass JR, Biden KG, Cummings MC, Simms LA, Walsh M, et al. (1999) Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. *J Clin Pathol* 52(6): 455–60.
64. Benhattar J, Losi L, Chaubert P, Givel JC, Costa L (1993) Prognostic significance of K-ras mutations in colorectal carcinoma. *Gastroenterology* 104(327): 293–297.
65. Lin RK, Hsu HS, Chang JW, Chen CY, Chen JT, et al. (2007) Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. *Lung Cancer* 55: 205–213.
66. Chow E, Lipton L, Lynch E, D'Souza R, Aragona C, et al. (2006) Hyperplastic polyposis syndrome: phenotypic presentations and the role of MBD4 and MYH. *Gastroenterology* 131(1): 30–9.